Ersoy Yeşil, EzgiYılmaz, YusufYeşil, AtakanMeşe, MeralKaya, EdaArı Bakır, Elif2023-01-312023-01-312023Ersoy Yeşil, E., Yılmaz, Y., Yeşil, A., Meşe, M., Kaya, E. & Arı Bakır, E. (2023). Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan. Hepatology Forum, 4(1), pp. 14-18. https://doi.org/10.14744/hf.2022.2022.00381307-58882757-7392https://doi.org/10.14744/hf.2022.2022.0038https://hdl.handle.net/20.500.13055/383Background & Aim: Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTR). In this study, we evaluated the prevalence of MAFLD among KTRs, a data that has not been investigated by any clinical study to date. Matherials and Methods: We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as control group through a prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan. Results: Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, CI 95%: 1.039-1.208). Conclusion: MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed.eninfo:eu-repo/semantics/openAccessFibroscanKidney Transplant RecipientsMafldArticle10.14744/hf.2022.2022.0038411418WOS:0009234804000042-s2.0-85164338674PMID: 368438891179038